The present data provide proof-of principle that CD103 blockade can prevent GVHD mortality mediated by donor CD8 T cells without compromising GVT effects, thus pointing to CD103 blockade as an inherently superior means of GVHD prophylaxis. This evidence concerns the gene CD8A and graft versus host disease.